|
Enter a Search String | Special character and space not allowed in the query term.
Search string should be at least 2 characters long. |
Molecule Parameter List for I1 | The statistics table lists the distribution of a molecule acting either as a substrate, product, enzyme or as a molecule within the network. The text color of a molecule is highlighted by color. | Statistics | Accession and Pathway Details | |
Accession Name | Accession No. | Accession Type | Pathway Link | Differential syn thesis of mRNA | 95 | Network | kinetics, compartment_1, compartment_2 | The model consists of three major pathways: Calcium-calmodulin dependent protein kinase IV (CaMKIV), Mitogen-activated protein kinase (MAPK) and Protein Phosphatase 1 (PP1). Each of these converged on CREB activation. We also modeled further interactions with Transducer of regulated CREB activity 1 (TORC1) and the protein kinase A (PKA) pathway. |
I1 acting as a Molecule in Differential synthesis of mRNA Network
Name | Accession Name | Pathway Name | Initial Conc. (uM) | Volume (fL) | Buffered | I1 | Differential syn thesis of mRNA Accession No. : 95 | kinetics Pathway No. : 1115 | 1.8 | 1000 | No | I1 is a 'mixed' inhibitor, but at high enz concs it looks like a non-compet inhibitor (Foulkes et al Eur J Biochem 132 309-313 9183). We treat it as non-compet, so it just turns the enz off without interacting with the binding site. Cohen et al ann rev bioch refer to results where conc is 1.5 to 1.8 uM. In order to get complete inhib of PP1, which is at 1.8 uM, we need >= 1.8 uM. |
I1 acting as a Substrate for an Enzyme in Differential synthesis of mRNA Network
Enzyme Molecule / Enzyme Activity | Accession Name | Pathway Name | Km (uM) | kcat (s^-1) | Ratio | Enzyme Type | Reagents | PKA_dash_active / PKA_dash_ phosph_dash_I1
| Differential syn thesis of mRNA Accession No. : 95 | kinetics Pathway No. : 1115 | 7.5 | 9 | 4 | explicit E-S complex | Substrate I1
Product I1_star
| #s from Bramson et al CRC crit rev Biochem 15:2 93-124. They have a huge list of peptide substrates and I have chosen high-ish rates. These consts give too much PKA activity, so lower Vmax 1/3. Now, k1 = 3e-5, k2 = 36, k3 = 9 (still pretty fast). Also lower Km 1/3 so k1 = 1e-5 Cohen et al FEBS Lett 76:182-86 1977 say rate =30% PKA act on phosphokinase beta. |
I1 acting as a Product of an Enzyme in Differential synthesis of mRNA Network
| Enzyme Molecule / Enzyme Activity | Accession Name | Pathway Name | Km (uM) | kcat (s^-1) | Ratio | Enzyme Type | Reagents | 1 | PP2A / PP2A_dash_ dephosph_dash_ I1
| Differential syn thesis of mRNA Accession No. : 95 | kinetics Pathway No. : 1115 | 7.8283 | 6 | 4.16666666667 | explicit E-S complex | Substrate I1_star
Product I1
| | PP2A does most of the dephosph of I1 at basal Ca levels. See the review by Cohen in Ann Rev Biochem 1989. For now, lets halve Km. k1 was 3.3e-6, now 6.6e-6 | 2 | CaNAB_dash_Ca4 / dephosph_ inhib1_noCaM
| Differential syn thesis of mRNA Accession No. : 95 | kinetics Pathway No. : 1115 | 4.9708 | 0.034 | 4 | explicit E-S complex | Substrate I1_star
Product I1
| | The rates here are so slow I do not know if we should even bother with this enz reacn. These numbers are from Liu and Storm. Other refs suggest that the Km stays the same but the Vmax goes to 10% of the CaM stim levels. Prev: k1=2.2e-9, k2 = 0.0052, k3 = 0.0013 New : k1=5.7e-8, k2=.136, k3=.034 | 3 | CaM_Ca_n_dash_ CaNAB / dephosph_inhib1 | Differential syn thesis of mRNA Accession No. : 95 | kinetics Pathway No. : 1115 | 4.9708 | 0.34 | 4 | explicit E-S complex | Substrate I1_star
Product I1
| | |
I1 acting as a Product in a reaction in Differential synthesis of mRNA Network
Kd is calculated only for second order reactions, like nA+nB <->nC or nA<->nC+nD, where n is number and A,B,C,D are molecules, where as for first order reactions Keq is calculated.
Kd for higher order reaction are not consider. |
| Database compilation and code copyright (C) 2022, Upinder S. Bhalla and NCBS/TIFR This Copyright is applied to ensure that the contents of this database remain freely available. Please see FAQ for details. |
|